Dominari HoldingsNASDAQ: DOMH

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Dominari Holdings is in the Healthcare sector

Dominari Holdings is in the Biotechnology industry

Dominari Holdings is headquartered in United States

Dominari Holdings initial public offering (IPO) was on 18 March 1980

https://www.aikidopharma.com

No, Dominari Holdings is not included in the S&P 500 index

No, Dominari Holdings is not included in the NASDAQ 100 index

No, Dominari Holdings is not included in the Dow Jones index